Physician profile
Maged S Samaan
NPI 1164447355
$1,550.81
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,314 · 2020: $237.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $323.08 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $298.58 | 2019-2020 | |
| Allergan, INC. | $263.62 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $236.47 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.20 | 2019 | |
| Amarin Pharma, INC. | $120.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.85 | 2019 | |
| Merck Sharp & Dohme LLC | $22.43 | 2019 | |
| Amgen INC. | $21.79 | 2020 | |
| Novo Nordisk INC | $20.90 | 2019 | |
| Lilly USA, LLC | $20.07 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.57 | 2019 | |
| Pfizer INC. | $15.03 | 2020 | |
| Mdd US Operations, LLC | $12.59 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maged Samaan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.